-0.00011645171620731 -0.00011645171620731 -0.00142653352353779 2.9112929051724E-05 -0.000407581006725171 0.000611371510087653 0.00279484118897192 0.00104806544586455
Sign Up Today X
Thanks for submitting the form.
Stockreport

Gilead Stock Surges on Strong Results in HIV Drug Study [Yahoo! Finance]

Gilead Sciences, Inc. (GILD)  More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants. More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval. Shares of Gilead surged Thursday following the news. Gilead Sciences ( GILD ) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in women. Gilead noted that the results were so successful that the independent Data Monitoring Committee (DMC) recommended that the company end the blind phase of the study and offer lenacapavir to all of the participants. Zero HIV Infections Among Women Who Took Gilead's Lenacapavir The trial found zero cases of HIV infection among the 2,134 women who received the treatment, versus several cases among those who took Gilead's current HIV pills, Truvada and Descovy. Truvada was the first pre-exposure [Read more]
IMPACT SNAPSHOT EVENT TIME: GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
GILD alerts
from News Quantified
GILD
NEWS
GILD
Earnings
GILD
Analyst Actions
GILD
SEC Filings
Stockreport

Gilead Stock Surges on Strong Results in HIV Drug Study [Yahoo! Finance]

Gilead Sciences, Inc.  (GILD) 
More Company Research Source: Yahoo! Finance
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
Gilead said the test results were so significant an independent monitor recommended the company give the drug to all participants. More testing is needed before Gilead can apply to the U.S. Food and Drug Administration for approval. Shares of Gilead surged Thursday following the news. Gilead Sciences ( GILD ) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in women. Gilead noted that the results were so successful that the independent Data Monitoring Committee (DMC) recommended that the company end the blind phase of the study and offer lenacapavir to all of the participants. Zero HIV Infections Among Women Who Took Gilead's Lenacapavir The trial found zero cases of HIV infection among the 2,134 women who received the treatment, versus several cases among those who took Gilead's current HIV pills, Truvada and Descovy. Truvada was the first pre-exposure [Read more]
IMPACT SNAPSHOT
EVENT TIME:
GILD
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS